In this study, we investigated whether high-dose AA in combination with anti-PD1 therapy exhibits anticancer effects in vitro and in a syngeneic lung cancer mouse model, and determined the changes in the immune microenvironment of the tumor tissue. The gene discussed is PDCD1; the disease is lung carcinoma.